These results were consistent with previous studies indicating that TP53 mutations were significantly enriched in high-risk and poorly differentiated HCC, whereas CTNNB1 mutations were predominantly associated with low-risk and well-differentiated HCC (Calderaro et al., 2017). Here, TP53 is linked to hepatocellular carcinoma.